Logo

The Role of Interferon Gamma Gene Polymorphism (+874A/T, +2109A/G, and -183G/T) in Response to Treatment Among Hepatitis C Infected Patients in Fars Province, Southern Iran

Author(s):
Jamal SarvariJamal Sarvari1, Hossin NorozianHossin Norozian1, Mohamad Reza FattahiMohamad Reza Fattahi2, Neda PirbonyehNeda Pirbonyeh1, Afagh MoattariAfagh MoattariAfagh Moattari ORCID1,*
1Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran


Hepatitis Monthly:Vol. 14, issue 1; 14476
Published online:Jan 22, 2014
Article type:Research Article
Received:Aug 26, 2013
Accepted:Oct 25, 2013
How to Cite:Jamal SarvariHossin NorozianMohamad Reza FattahiNeda PirbonyehAfagh MoattariThe Role of Interferon Gamma Gene Polymorphism (+874A/T, +2109A/G, and -183G/T) in Response to Treatment Among Hepatitis C Infected Patients in Fars Province, Southern Iran.Hepat Mon.14(1):14476.https://doi.org/10.5812/hepatmon.14476.

Abstract

Background:

Hepatitis C virus (HCV) infection as a worldwide health problem is associated with cirrhosis and hepatocellular carcinoma. With current treatment regimen, pegylated interferon (PEG-IFN) plus ribavirin, sustain virological response (SVR) is achieved in only 50% of infected individuals. In HCV infection, an inappropriate ratio of cytokines may affect the benefit of antiviral therapy. Given the polymorphisms in regulatory regions of cytokines genes may influence cytokines production.

Objectives:

We aimed to investigate both the frequency of genotypes and alleles of interferon gamma (IFN-?) gene at +874A/T, +2109A/G, and -183G/T loci in HCV-infected patients and their associations with response to therapy.

Patients and Methods:

A total of 158 patients were included and treated with PEG-IFN plus ribavirin. The presence of HCV infection in patients was confirmed by reverse transcription polymerase chain reaction, and genomic DNA was extracted from peripheral leukocytes using salting out method. IFN-? gene polymorphisms were identified by polymerase chain reaction using sequence specific primers and restriction fragment length polymorphism analysis on genomic DNA.

Results:

Of 158 patients, 110 (69.5%) subjects achieved SVR and 48 (30.5%) subjects did not respond to therapy. The frequency of AA genotype (P = 0.001; OR: 11.2; CI: 2.26-63.21) and A allele (P = 0.01; OR: 3.23; CI: 1.23 8.56) of IFN-? gene at +2109 locus were significantly different between the responder and non-responder subjects infected with genotype 1. Regardless of HCV genotype, the frequency of AG genotype was also higher in responder group than those who did not respond to therapy (P = 0.041; OR: 05.05; CI: 1.05-33.25)). In case of IFN-? gene at +874 locus, there was no difference in genotypes and alleles frequencies between the responder and non-responder subjects infected with HCV genotypes 1 and 3. Haplotype analysis showed no association between haplotypes and response to therapy. All participants had G/T genotype at -183 locus.

Conclusions:

Our findings indicate that heterogeneity at +2109 locus of IFN-? gene but not at +874 locus could interfere with successful therapy in patients infected with HCV genotype 1.

Full Text

Full text is available in PDF

comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles